Background {#Sec1}
==========

Aging issues are very important because the elderly (≥ 65 years old) are expected to increase rapidly from 6.2% of the world population in 1992 to 20% by 2050 \[[@CR1]\]. In Taiwan, the geriatric population increased from 7% in 1993 to 12.5% in 2015 \[[@CR2]\] and is expected to grow to 20% in 2025 \[[@CR3]\]; Taiwan is one of the most rapidly aging countries in the world. The increasing geriatric population needs more medical healthcare resources, which reached 33.5% expenditure of Taiwan National Health Insurance in 2011; this percentage still rises \[[@CR3]\].

Septic arthritis (SA) is a common joint infection \[[@CR4]\] and is often caused by bacteria, viruses, or other less-common pathogens \[[@CR4]\]. SA usually involves single and large joints, such as the knee joint, but many others may be involved \[[@CR4]\]. In the United States, the incidence rate of SA is 0.01% in the general population annually; however, it increases to 0.07% in the high-risk groups such as those with rheumatoid arthritis or a prosthetic joint \[[@CR5]\]. The predisposing factors for SA are as follows: (1) age \> 80 years; (2) weak immune system due to diabetes, renal, and liver diseases, human immunodeficiency virus (HIV) infection, and use of immune-suppression drugs; (3) alcohol abuse; (4) cancer; (5) rheumatoid arthritis; (6) presence of prosthetic joint; (7) recent joint surgery; (8) skin infection; and (9) prior intra-articular corticosteroid injection \[[@CR4]--[@CR6]\].

Geriatric population is more vulnerable to SA because they have more risk factors than the younger population. The mortality for SA in geriatric patients is also higher than that in younger population due to delayed diagnosis and treatment, underlying comorbidities, and decreased physiological reserve \[[@CR7]\]. Previous studies about geriatric SA are rare and focused on the identifications of the risk factors or treatments \[[@CR8], [@CR9]\]; however, the long-term mortality and mortality predictors after SA have never been clarified. Therefore, we conducted this nationwide population-based cohort based on Taiwan's National Health Insurance Research Database (NHIRD) to determine the risk for long-term mortality in geriatric patients with SA as well as the mortality predictors.

Methods {#Sec2}
=======

Data sources {#Sec3}
------------

Taiwan launched a National Health Insurance program including almost all Taiwan's citizens since March 1st, 1995 \[[@CR10]\]. Large computerized databases containing the data of registration and claim diagnosis for reimbursement are derived from this system through the National Health Insurance Administration, Ministry of Health and Welfare, Taiwan and are maintained by the National Health Research Institutes, Taiwan; the databases are provided to scientists in Taiwan for research \[[@CR10]\]. This study was based on the Longitudinal Health Insurance Database 2000 (LHID2000), which contains the entire original claim data of 1,000,000 beneficiaries enrolled in year 2000, randomly selected from the original NHIRD \[[@CR10]\].

Study design, participants, and definitions of the variables {#Sec4}
------------------------------------------------------------

Using LHID2000, we conducted a prospective nationwide population-based cohort study. We first identified all geriatric participants (age ≥ 65 years) and excluded those who had SA (ICD-9 code: 711.0) before 1999 (Fig. [1](#Fig1){ref-type="fig"}). We excluded participants with SA before 1999 to include new-onset SA only because this method could help us use the index date (i.e., the date of diagnosis for SA in the geriatric participants with SA) to match the comparison cohort and Cox proportional hazard regression to compare the risk for mortality. Next, we matched geriatric participants with and without SA between the period of January 1st, 1999 and December 31, 2010. These subjects were selected as the study cohort and the comparison cohort, respectively, matched at a ratio of 1:10 by age, sex, and index date. For stratified analysis, we categorized geriatric participants into three age subgroups: young elderly (65--74 years), moderately elderly (75--84 years), and old elderly (≥ 85 years), which is the most common criteria in the literatures \[[@CR11], [@CR12]\]. The underlying comorbidities that affect mortality included in this study were defined as follows: coronary artery disease (ICD-9 codes 410--414), congestive heart failure (ICD-9 code 428), chronic pulmonary obstructive disease (ICD-9 code 496), stroke (ICD-9 codes 436--438), osteoarthritis (ICD-9 code 715), diabetes (ICD-9 code 250), gout (ICD-9 code 274), renal disease (ICD-9 codes 582, 583, 585, 586, and 588), liver disease (ICD-9 codes 570--573), cancer (ICD-9 codes 140--208), rheumatoid arthritis (ICD-9 code 714), systemic lupus erythematosus (ICD-9 code 710.0), alcoholism (ICD-9 codes 291, 303), and HIV infection (ICD-9 codes 042--044). We also classified the affected areas as upper limbs (ICD-9 codes 711.01--711.04) and lower limbs (ICD-9 codes 711.05--711.07). Unspecified and multiple sites were excluded from the analysis concerning differences among affected sites due to the difficulty of classification. We followed up the participants until the end of 2011 to compare the all-cause mortality risk between both cohorts. According to the law in Taiwan, all citizens or people owning a residence permit are mandatory to participate in the National Health Insurance, and they must be dropped out of the National Health Insurance within 30 days after death. Therefore, we defined the death as the participant had the diagnosis of death or withdrew from the National Health Insurance. Stratified analyses by age subgroups and sex were performed to evaluate the effect modification of age and sex.Fig. 1Flowchart of the study. NHIRD, National Health Insurance Research Database

Ethic statements {#Sec5}
----------------

This study was approved by the Institutional Review Board at Chi-Mei Medical Center and conducted according to the Declaration of Helsinki. Because the LHID2000 used in this study consists of unidentifiable and secondary data released to the public for research, informed consent was waived. The waiver does not affect the rights and welfare of the participants.

Statistical analysis {#Sec6}
--------------------

SAS 9.3.1 for Windows (SAS Institute, Cary, NC, USA) was used for all statistical analyses. In the comparison of age, sex, and underlying comorbidities between the two cohorts, we used Pearson chi-square tests for categorical variables and independent *t* test for continuous variables. Cox proportional hazard regression analysis with adjustment for coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, stroke, osteoarthritis, diabetes, gout, renal disease, liver disease, cancer, rheumatoid arthritis, systemic lupus erythematosus, and alcoholism was used to compare the mortality risk between the two cohorts. Kaplan-Meier curve and log-rank test for comparing mortality between participants with and without SA was also performed. Finally, we investigated the independent mortality predictor by Cox proportional hazard regression analysis. Significance level was set at 0.05 (two-tailed). Due to the simple covariate adjustment within Cox models may not fully adjust for such imbalance, and unmeasured confounder may exist \[[@CR13]\]. Thus, we also conducted additional sensitivity analysis for the unmeasured confounder to strengthen the article base on the proposed method of Lin et al. (Appendix: Table [4](#Tab4){ref-type="table"}).

Results {#Sec7}
=======

The mean age in both cohorts was 74.6 years and the majority of geriatric participants were within the subgroup age 65--74 years (approximately 53%) (Table [1](#Tab1){ref-type="table"}). The sex ratio was nearly equal in both cohorts. The common underlying comorbidities in the geriatric participants with SA were coronary artery disease (20.6%), congestive heart failure (8.4%), chronic pulmonary obstructive disease (17.3%), stroke (14.8%), osteoarthritis (32.3%), diabetes (28.6%), gout (17.4%), renal disease (9.9%), liver disease (9.5%), cancer (6.2%), rheumatoid arthritis (2.2%), and alcoholism (0.1%). There was no HIV infection in the participants. In the comparison of underlying comorbidities, geriatric participants with SA had significantly higher prevalence of coronary artery disease, congestive heart failure, chronic pulmonary obstructive disease, stroke, osteoarthritis, diabetes, gout, renal disease, liver disease, cancer, rheumatoid arthritis, and systemic lupus erythematosus than those without SA (all *p*-value \<0.001).Table 1Demographic characteristics for geriatric participants with and without SAVariableWith SA\
(*n* = 1667)Without SA\
(*n* = 16,670)*p*-valueAge (years, mean ± SD)74.6 ± 6.774.6 ± 6.60.764Age (years)0.945 65--74893 (53.6)8964 (53.8) 75--84619 (37.1)6197 (37.2) ≥85155 (9.3)1509 (9.1)Sex\>0.999 Female843 (50.6)8430 (50.6) Male824 (49.4)8240 (49.4)Underlying comorbidity Coronary artery disease343 (20.6)2065 (12.4)\<0.001 Congestive heart failure140 (8.4)478 (2.9)\<0.001 Chronic pulmonary obstructive disease288 (17.3)1640 (9.8)\<0.001 Stroke247 (14.8)1484 (8.9)\<0.001 Osteoarthritis539 (32.3)1753 (10.5)\<0.001 Diabetes477 (28.6)2828 (17.0)\<0.001 Gout290 (17.4)752 (4.5)\<0.001 Renal disease165 (9.9)482 (2.9)\<0.001 Liver disease158 (9.5)717 (4.3)\<0.001 Cancer103 (6.2)680 (4.1)\<0.001 Rheumatoid arthritis36 (2.2)60 (0.4)\<0.001 Systemic lupus erythematosus9 (0.5)8 (0.1)\<0.001 Alcoholism1 (0.1)7 (0.04)0.534 HIV infection00-Data are expressed as mean ± SD or n (%)*SA* septic arthritis, *HIV* human immunodeficiency virus

Geriatric participants with SA had a significantly higher mortality risk than those without SA \[adjusted hazard ratio (AHR): 1.39, 95% confidence interval (CI): 1.25--1.55\] (Table [2](#Tab2){ref-type="table"}). Older geriatric participants had higher mortality risk than the younger (AHRs in 65--74, 75--84, and ≥ 85 years old were 1.26, 1.44, and 1.86, respectively). Stratified analysis by sex showed there was a higher mortality risk in the male population than in female population. In the stratified analysis by the follow-up period, geriatric participants with SA had the highest mortality risk as compared with those without SA in the first 6 months after diagnosis (AHR: 3.38, 95% CI: 2.52--4.54). The impact of SA on mortality lasted until 1--2 years (AHR: 1.49, 95% CI: 1.11--1.98). Kaplan-Meier curve and log-rank test also showed that participants with SA had a lower survival than participants without SA during the follow-up (*p*-value \< 0.001) (Fig. [2](#Fig2){ref-type="fig"}).Table 2Comparison of mortality risk between geriatric participants with and without SA using Cox proportional hazard regression analysisVariableWith SAWithout SACrude HR (95% CI)Adjusted HR^a^ (95% CI)*n*Number of deathPYRate*n*Number of deathPYRateAll16674309437.16455.6516,6702545104,188.3244.271.87 (1.69--2.07)1.39 (1.25--1.55)Age (years) 65--748931675612.95297.538964107560,096.6178.881.67 (1.42--1.96)1.26 (1.06--1.50) 75--846191963215.66609.526197120636,364.3331.641.85 (1.59--2.15)1.44 (1.23--1.68) ≥ 8515567608.551100.9815092647727.47341.643.15 (2.41--4.12)1.86 (1.39--2.51)Sex Female8431915069.5376.768430118453,837.31219.921.71 (1.47--2.00)1.33 (1.13--1.56) Male8242394367.66547.28240136150,350.98270.302.03 (1.77--2.32)1.47 (1.27--1.70)Follow-up period 1--6 months166786795.71080.8116,6701528166.58186.125.73 (4.39--7.47)3.38 (2.52--4.54) 6--12 months153039740.5526.6716,0101717807.51219.022.40 (1.70--3.40)1.61 (1.10--2.35) 1--2 years1427621344.36461.1915,18533214,472.93229.392.01 (1.53--2.64)1.49 (1.11--1.98) 2--4 years1257882225.73395.3813,69557124,604.46232.071.70 (1.36--2.13)1.20 (0.94--1.51) 4--6 years974611694.27360.0410,95346119,194.34240.181.50 (1.15--1.96)1.18 (0.90--1.56)  \> 6 years725942636.6356.52830885829,942.47286.551.24 (1.01--1.54)1.07 (0.86--1.34)Data are expressed as mean ± SD or n (%)*SA* septic arthritis, *AHR* adjusted hazard ratio, *CI* confidence interval, *PY* person-year^a^Adjusted by coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, stroke, osteoarthritis, diabetes, gout, renal disease, liver disease, cancer, rheumatoid arthritis, systemic lupus erythematosus, and alcoholism Fig. 2Kaplan-Meier curve and log-rank test between participants with SA and without SA (outcome = mortality)

After Cox proportional hazard regression analysis, we found that SA (AHR: 1.23, 95% CI: 1.08--1.40), older age (≥ 85 and 75--84: AHR 2.18, 95% CI 1.93--2.47, and AHR 1.82, 95% CI 1.68--1.97, respectively), male sex (AHR: 1.23, 95% CI: 1.15--1.33), underlying comorbidities of congestive heart failure (AHR: 1.29, 95% CI: 1.10--1.51), chronic pulmonary obstructive disease (AHR: 1.49, 95% CI: 1.35--1.65), stroke (AHR: 1.66, 95% CI: 1.50--1.84), diabetes (AHR: 1.69, 95% CI: 1.55--1.83), gout (AHR: 1.25, 95% CI: 1.10--1.43), renal disease (AHR: 2.29, 95% CI: 2.00--2.62), liver disease (AHR: 1.51, 95% CI: 1.32--1.73), cancer (AHR: 1.74, 95% CI: 1.51--2.01), and rheumatoid arthritis (AHR: 1.55, 95% CI: 1.02--2.34) were independent mortality predictors (Table [3](#Tab3){ref-type="table"}). Participants with SA affected in lower limbs had a lower mortality than in upper limbs.Table 3Independent predictors for mortality in the total participants using Cox proportional hazard regression analysisVariableCrude HR (95% CI)AHR (95% CI)\**p*-value†Cohort With SA1.87 (1.69--2.07)1.23 (1.08--1.40)0.002 Without SA11Age (years) 65--7411 75--841.90 (1.76--2.05)1.82 (1.68--1.97)\<0.001 ≥ 852.14 (1.89--2.41)2.18 (1.93--2.47)\<0.001Sex Female11 Male1.26 (1.17--1.35)1.23 (1.15--1.33)\<0.001Underlying comorbidity Coronary artery disease1.48 (1.35--1.63)1.10 (0.99--1.21)0.069 Congestive heart failure2.54 (2.20--2.94)1.29 (1.10--1.51)0.001 Chronic pulmonary obstructive disease2.09 (1.90--2.29)1.49 (1.35--1.65)\<0.001 Stroke2.21 (2.01--2.44)1.66 (1.50--1.84)\<0.001 Osteoarthritis1.07 (0.97--1.19)0.99 (0.89--1.11)0.929 Diabetes1.94 (1.79--2.10)1.69 (1.55--1.83)\<0.001 Gout1.62 (1.42--1.84)1.25 (1.10--1.43)0.001 Renal disease3.76 (3.31--4.27)2.29 (2.00--2.62)\<0.001 Liver disease1.85 (1.62--2.11)1.51 (1.32--1.73)\<0.001 Cancer1.90 (1.65--2.18)1.74 (1.51--2.01)\<0.001 Rheumatoid arthritis1.86 (1.23--2.80)1.55 (1.02--2.34)0.039 Systemic lupus erythematosus0.96 (0.31--2.99)0.62 (0.20--1.93)0.411 Alcoholism0.74 (0.10--5.24)0.81 (0.11--5.73)0.829Affected area Upper limbs (*n* = 109)1.001.00 Lower limbs (*n* = 585)0.88 (0.62--1.25)0.69 (0.57--0.84)\<0.001*SA* septic arthritis, *HR* hazard ratio, *CI* confidence interval, *PY* person-year\*Adjusted by coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, stroke, osteoarthritis, diabetes, gout, renal disease, liver disease, cancer, rheumatoid arthritis, systemic lupus erythematosus, and alcoholism†For AHR

Discussion {#Sec8}
==========

This prospective nationwide population-based cohort study revealed that geriatric participants with SA had a significantly higher mortality risk than those without SA. The common underlying comorbidities in geriatric participants with SA were osteoarthritis, diabetes, coronary artery disease, chronic pulmonary obstructive disease, gout, stroke, renal disease, liver disease, congestive heart failure, cancer, and rheumatoid arthritis. SA impacted the mortality risk more markedly in the first 6 months after the diagnosis and its effect lasted until 1--2 years. The mortality in older geriatric participants was affected by SA more frequently than that in younger geriatric participants. Male sex, older age, congestive heart failure, chronic pulmonary obstructive disease, stroke, diabetes, gout, renal disease, liver disease, cancer, and rheumatoid arthritis were also independent mortality predictors.

Advancing age is itself a risk factor and a mortality predictor for SA \[[@CR14]\]. A single hospital-based study for SA reported that 61.4% of patients were \>60 years and 12.5% of patients were ≥80 years \[[@CR14]\]. The hospital mortality rate increased with age: 0.7% of patients \<60 years, 4.8% of those 60--79 years, and 9.5% of those ≥80 years \[[@CR14]\]. Another study reported that despite surgical treatment in the geriatric patients with SA, the complications were still high: 38% had osteomyelitis, 14% had secondary osteoarthritis, and 19% showed mortality due to sepsis \[[@CR15]\]. In addition to the decreased immunity and increased comorbidities in the geriatric patients, the other explanation was that the diagnosis of infection in the elderly is more difficult due to the atypical manifestations \[[@CR7]\]. Positive outcome needs an early diagnosis and treatment \[[@CR7], [@CR15]\]. The explanation for increased long-term mortality in geriatric participants with SA is multi-factorial. One of them is the dysfunction of the joint despite proper treatment, which results in subsequent disability of daily activity \[[@CR16]\]. A study reported that severe activity of daily life (ADL) limitations and receiving ADL assistance significantly increased the subsequent mortality \[odds ratio (OR): 19.75, 95% CI 9.81--39.76 and OR: 16.57, 95% CI 8.39--32.73, respectively\] \[[@CR17]\]. Another study reported that the disability for at least one ADL item predicted in-hospital death in the admitted geriatric patients (OR: 2.16, 95% CI: 1.55--2.99) \[[@CR18]\]. A population-based study in the Netherlands reported that there was an increased mortality risk in the disabled population than in the non-disabled population \[[@CR19]\]. Severe disability may has an independent effect for mortality despite that the risk factors preceding the disability could explain the difference in mild disability \[[@CR19]\].

Inflammation after SA or its complications is also a possible mechanism for increasing the mortality \[[@CR20]\]. A study about acute-care hospitalized elderly patients reported that C-reactive protein (CRP) ≥ 30 mg/l predicted mortality (OR: 3.72, 95% CI: 1.34--10.31) \[[@CR18]\]. SA may result in subsequent osteomyelitis \[[@CR15]\] or chronic SA, which may cause a chronic inflammation and increase long-term mortality \[[@CR21]\]. A nationwide population-based cohort study reported that geriatric participants with chronic osteomyelitis had a significantly higher mortality risk than those without chronic osteomyelitis \[incidence rate ratio (IRR): 2.29, 95% CI: 2.01--2.59\] \[[@CR21]\]. The mortality risk was highest in the first month (IRR: 5.01, 95% CI: 2.02--12.42) and still higher even after 6 years (IRR: 1.53, 95% CI: 1.13--2.06) of follow-up \[[@CR21]\]. This study did not analyze the cause of chronic osteomyelitis; however, it did provide us an insight into the effect of chronic osteomyelitis, a common complication after SA. In addition to ADL limitations and inflammation, the possible explanations for highest mortality risk in the first 6 months after the diagnosis are disseminated infection, acute renal failure, and cardiopulmonary failure \[[@CR22]\].

We showed that joints of the lower limbs were more affected than those of the upper limbs (*n* = 585 vs. *n* = 109), which was consistent with previous studies that showed that large joints in the lower limbs, such as knee and hip, were more commonly involved than small joints \[[@CR14]--[@CR16], [@CR22]\]. The present study showed that SA in the lower limbs had a lower mortality than in upper limbs. However, a previous study reported that SA involving the hip or shoulder predicted poor outcome \[[@CR23]\], which suggests that the comparison of outcome between the upper or lower limbs warrants more study in the future.

We showed that male sex, older age, congestive heart failure, chronic pulmonary obstructive disease, stroke, diabetes, gout, renal disease, liver disease, cancer, and rheumatoid arthritis also predicted mortality; however, systemic lupus erythematosus, a risk factor for SA \[[@CR24]\], did not predict mortality. It suggests that we should treat SA as well as control other comorbidities simultaneously to decrease the subsequent mortality.

The strength of this study was that it clarified the long-term mortality and independent mortality predictors in geriatric participants with SA, which remained unclear. Despite its strength, this study had some limitations. First, the NHIRD contains no information on the severity of SA, some important laboratory data such as pathogens of blood culture or synovial fluid, and participants' social economic status and post-diagnosis health care conditions (e.g., received good or bad quality health care? stay at home or in hospital or in nursing home?); therefore, we were unable to evaluate the severity association between them. Studies with more detail information are needed for the causal relationship between mortality and SA. Second, we did not identify the drug use, definite infected joints, and the relationship with previous surgery or prosthesis. Third, categorization of age is more convenient for clinical use; however, it may loss some information. Fourth, although our study was a nationwide population-based study, the result may not be applied to other nations due to the differences in race, culture, and environment.

Conclusions {#Sec9}
===========

This prospective nationwide population-based cohort study showed that long-term mortality was significantly higher in geriatric participants with SA than in those without SA. The influence was highest in the first 6 months after diagnosis and lasted until 1--2 years. The impact of SA on mortality was more pronounced in the older geriatric participants than in the younger geriatric participants. In addition to SA, male sex, older age, congestive heart failure, chronic pulmonary obstructive disease, stroke, diabetes, gout, renal disease, liver disease, cancer, and rheumatoid arthritis were independent mortality predictors. For the increasing aging population worldwide, strategies for the prevention and treatment of SA and concomitant control of comorbidities are very important.

Appendix {#Sec10}
========

Table 4Sensitivity analysis for the residual confounding effects of unmeasured variable after adjusting for measured covariatesP~0~rP~1~00.10.20.30.40.5201.231.3531.4761.5991.7221.845(1.080,1.400)(1.188,1.540)(1.296,1.680)(1.404,1.820)(1.512,1.960)(1.620,2.100)0.21.0251.1271.231.3331.4351.537(0.900,1.167)(0.990,1.283)(1.080,1.400)(1.170,1.517)(1.260,1.633)(1.350,1.750)0.40.8790.9661.0541.1421.231.318(0.771,1.000)(0.849,1.100)(0.926,1.200)(1.003,1.300)(1.080,1.400)(1.157,1.500)0.60.7690.8460.9220.9991.0761.153(0.675,0.875)(0.743,0.962)(0.810,1.050)(0.878,1.137)(0.945,1.225)(1.013,1.312)0.80.6830.7520.820.8880.9571.025(0.600,0.778)(0.660,0.856)(0.720,0.933)(0.780,1.011)(0.840,1.089)(0.900,1.167)10.6150.6760.7380.80.8610.922(0.540,0.700)(0.594,0.770)(0.648,0.840)(0.702,0.910)(0.756,0.980)(0.810,1.050)601.231.8452.463.0753.694.305(1.080,1.400)(1.620,2.100)(2.160,2.800)(2.700,3.500)(3.240,4.200)(3.780,4.900)0.20.6150.9221.231.5371.8452.153(0.540,0.700)(0.810,1.050)(1.080,1.400)(1.350,1.750)(1.620,2.100)(1.890,2.450)0.40.410.6150.821.0251.231.435(0.360,0.467)(0.540,0.700)(0.720,0.933)(0.900,1.167)(1.080,1.400)(1.260,1.633)0.60.3070.4610.6150.7690.9231.076(0.270,0.350)(0.405,0.525)(0.540,0.700)(0.675,0.875)(0.810,1.050)(0.945,1.225)0.80.2460.3690.4920.6150.7380.861(0.216,0.280)(0.324,0.420)(0.432,0.560)(0.540,0.700)(0.648,0.840)(0.756,0.980)10.2050.3070.410.5130.6150.718(0.180,0.233)(0.270,0.350)(0.360,0.467)(0.450,0.583)(0.540,0.700)(0.630,0.817)1001.232.3373.4444.5515.6586.765(1.080,1.400)(2.052,2.660)(3.024,3.920)(3.996,5.180)(4.968,6.440)(5.940,7.700)0.20.4390.8351.231.6252.0212.416(0.386,0.500)(0.733,0.950)(1.080,1.400)(1.427,1.850)(1.774,2.300)(2.121,2.750)0.40.2670.5080.7490.9891.231.471(0.235,0.304)(0.446,0.578)(0.657,0.852)(0.869,1.126)(1.080,1.400)(1.291,1.674)0.60.1920.3650.5380.7110.8841.057(0.169,0.219)(0.321,0.416)(0.472,0.612)(0.624,0.809)(0.776,1.006)(0.928,1.203)0.80.150.2850.420.5550.690.825(0.132,0.171)(0.250,0.324)(0.369,0.478)(0.487,0.632)(0.606,0.785)(0.724,0.939)10.1230.2340.3440.4550.5660.676(0.108,0.140)(0.205,0.266)(0.302,0.392)(0.400,0.518)(0.497,0.644)(0.594,0.770)

ADL

:   activity of daily life

AHR

:   adjusted hazard ratio

CI

:   confidence interval

CRP

:   C-reactive protein

HIV

:   human immunodeficiency virus

ICD

:   International Classification of Diseases

IRR

:   incidence rate ratio

LHID

:   Longitudinal Health Insurance Database

NHIRD

:   National Health Insurance Research Database

OR

:   odds ratio

SA

:   septic arthritis
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